COMPASS Pathways (CMPS) Is Down 8.6% After Phase 3 Durability Data For COMP360 In TRD

COMPASS Pathways was down 8.6% after publishing Phase 3 durability data for COMP360 in treatment-resistant depression, alongside ongoing regulatory progress toward a possible 2027 launch. The company previously reported 26-week results from its second Phase 3 COMP006 trial, describing rapid onset, durable clinical benefit, and a generally well-tolerated safety profile while advancing a rolling New Drug Application with the FDA. A referenced Part B readout said 39% of patients on 25 mg achieved clinically meaningful improvement on the MADRS by week 6 and maintained benefit through week 26. The update also included a post-hoc analysis from a Phase 2 PTSD study suggesting improvements may stem mainly from the psilocybin experience rather than traditional psychotherapy. The article frames the market narrative around regulatory timing, launch costs, safety or efficacy changes, and potential additional financing needs, noting analysts previously modeled far lower 2029 revenues.